Atrial Fibrillation - Pipeline Review, H2 2015 Now Available at iData Insights Atrial Fibrillation - Pipeline Review, H2 2015 Summary Global Markets Direct s, Atrial Fibrillation Pipeline Review, H2 2015 , provides an overview of the Atrial Fibrillation s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects. Global Markets Direct s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Atrial Fibrillation - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Atrial Fibrillation and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects A review of the Atrial Fibrillation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Atrial Fibrillation pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Atrial Fibrillation - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Atrial Fibrillation pipeline depth and focus of Indication therapeutics 1
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Browse Complete Report with TOC @ http://www.idatainsights.com/reports-landingpage.php?id=124212/atrial-fibrillation-pipeline-review-h2-2015 To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=124212/atrial-fibrillation-pipeline-review-h2-2015 Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Atrial Fibrillation Overview 9 Therapeutics Development 10 Pipeline Products for Atrial Fibrillation - Overview 10 Pipeline Products for Atrial Fibrillation - Comparative Analysis 11 Atrial Fibrillation - Therapeutics under Development by Companies 12 Atrial Fibrillation - Therapeutics under Investigation by Universities/Institutes 14 Atrial Fibrillation - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Atrial Fibrillation - Products under Development by Companies 18 Atrial Fibrillation - Products under Investigation by Universities/Institutes 20 Atrial Fibrillation - Companies Involved in Therapeutics Development 21 ARCA biopharma, Inc. 21 Armetheon, Inc. 22
2
AstraZeneca Plc 23 Bristol-Myers Squibb Company 24 Cardiome Pharma Corp. 25 Daiichi Sankyo Company, Limited 26 Gilead Sciences, Inc. 27 Isis Pharmaceuticals, Inc. 28 Laboratoires Pierre Fabre SA 29 Nissan Chemical Industries, Ltd. 30 Nyken BV 31 Otsuka Holdings Co., Ltd. 32 Xention Limited 33 Atrial Fibrillation - Therapeutics Assessment 34 Assessment by Monotherapy Products 34 Assessment by Target 35 Assessment by Mechanism of Action 37 Assessment by Route of Administration 39 Assessment by Molecule Type 41 Drug Profiles 43 AT-300 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 BMS-394136 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 BMS-919373 - Drug Profile 46 3
Product Description 46 Mechanism of Action 46 R&D Progress 46 bucindolol hydrochloride - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 budiodarone - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 edoxaban tosylate - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 F-373280 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 ISIS-CRPRx - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 NIP-151 - Drug Profile 55 Product Description 55 Mechanism of Action 55
4
R&D Progress 55 NYK-1112 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 OMT-33 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 OPC-108459 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 ranolazine ER - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Small Molecule to Block Calcium-Activated Potassium Channel for Atrial Fibrillation - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 Small Molecule to Block Kv1.5, Nav1.5, IKACh for Atrial Fibrillation - Drug Profile 64 Product Description 64 5
Mechanism of Action 64 R&D Progress 64 Small Molecules to Block Voltage Gated Sodium Channel for Atrial Fibrillation - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 vanoxerine - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 vernakalant hydrochloride - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 XEN-R0702 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 XEND-0103 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 XENR-0703 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72
6
XENR-0706 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Atrial Fibrillation - Recent Pipeline Updates 74 Atrial Fibrillation - Dormant Projects 88 Atrial Fibrillation - Discontinued Products 92 Atrial Fibrillation - Product Development Milestones 94 Featured News & Press Releases 94 Sep 23, 2015: UK s NICE recommends once-daily LIXIANA (edoxaban) for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation 94 Sep 14, 2015: Laguna Pharmaceuticals Initiates Phase 3 Study of Vanoxerine in Atrial Fibrillation and Atrial Flutter 95 Jul 24, 2015: Cardiome Partner Eddingpharm to Initiate BRINAVESS Phase I Study in China 95 Jul 09, 2015: New Therapy to Help Heart Rhythm Patients Means Doctors are "Spoilt for Choice" 96 Jun 25, 2015: Daiichi Sankyo s Once-Daily LIXIANA (edoxaban) Approved in the EU for Stroke Prevention in Nonvalvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent DVT and PE 98 Jun 12, 2015: Independent Study Finds Intravenous Vernakalant Facilitates Electrical Cardioversion in Patients with Cardioversion Resistant Atrial Fibrillation 100 Apr 27, 2015: Daiichi Sankyo s Once-Daily Lixiana (edoxaban) Receives Positive CHMP Opinion for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Europe 101 Apr 15, 2015: Daiichi Sankyo s Once-Daily Lixiana (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Switzerland 102 Apr 09, 2015: Cardiome Receives BRINAVESS Reimbursement Approval From Belgian Authorities 104 Feb 09, 2015: SAVAYSA (edoxaban) Now Available in U.S. Pharmacies 104 Appendix 106 Methodology 106 Coverage 106
7
Secondary Research 106 Primary Research 106 Expert Panel Validation 106 Contact Us 106 Disclaimer 107 Read More http://www.idatainsights.com/reports-landing-page.php?id=124212/atrial-fibrillationpipeline-review-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects
8